ReviewHealthcare (Basel, Switzerland)2023
Leveraging Technology to Diagnose Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Review in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An Overview of Reviews on Telemedicine and Telehealth in Dementia Care: Mixed Methods Synthesis.JMIR mental health · 2025Review
- Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy.Science translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbout 50 million people worldwide suffered from dementia in 2018-two-thirds of those with Alzheimer's disease (AD). By 2050, this number is expected to rise to 152 million-which is slightly larger than the country of Russia. About 90% of these people are over the age of 65, but early-onset dementia can occur at younger ages. Early detection is imperative to expedient treatment, which can improve outcomes over the span of diagnosis.
objectivesTo conduct a meta-analysis of similar studies along with a systematic literature review to hasten the development of clinical practice guidelines to assist clinicians in the diagnosis of AD. We analyzed data points in each article published over the last 10 years to meet this objective: cost, efficiency, accuracy, acceptability (by physician and patient), patient satisfaction, and barriers to adoption.
methodsFour research databases were queried (PubMed, CINAHL Ultimate, Web of Science, and ScienceDirect). The review was conducted in accordance with a published protocol, the Kruse Protocol, and reported in accordance with PRISMA (2020).
resultsTen interventions were identified to help diagnose AD among older patients, and some involved a combination of methods (such as MRI and PET). The average sample size was 320.32 (SD = 437.51). These 10 interventions were identified as accurate, non-invasive, non-stressful, inexpensive, convenient, and rapid. Only one intervention was identified as statistically ineffective, and this same intervention was used effectively in other studies. The barriers identified were cost, training, expense of travel, and required physical presence of patient. The weighted average sensitivity was 85.16%, specificity was 88.53, and the weighted average effect size was 0.7339 (medium).
conclusionInnovation can accurately diagnose AD, but not all methods are successful. Providers must ensure they have the proper training and familiarity with these interventions to ensure accuracy in diagnosis. While the physical presence of the patient is often required, many interventions are non-invasive, non-stressful, and relatively inexpensive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.